March 28, 2012
Asia-Pac Clinical Research – Regulatory Environment
|Speaker panel from Max Neeman International:
Renu Razdan, PhD, Chief Operating Officer
Vandana Pandey, Manager Regulatory Affairs
Donald Swankie, MBA, Vice President, USA |
Asia-Pac Clinical Research – Regulatory Environment
India has become an attractive destination for clinical trials, combining many of the elements western sponsors require including: a vibrant urban health care environment, English as the language of clinical trials, first rate medical credentials of CRAs and Project Managers, and an advanced clinical trial infrastructure.
Indeed, Indian based regulatory bodies cooperate fully with international agencies, to ensure regulatory standards meet the requirements of USA FDA and ICH GCP guidelines. As a result of the Indian government’s initiatives, the FDA established it’s second ‘ex-USA’ office in India in 2009.
The country’s regulatory authorities are committed to progressive review and approval of foreign clinical research requests, willing to learn from and improve upon methods when challenges are faced. They continue preparing in anticipation of increasing growth from around the world to conduct their clinical trial studies in India.
Still, with growth and change, as within any other Government regulatory body, Sponsor updates about time to approval, involvement of agencies in the approval process, and processing of import/export licenses, retain a high priority, with Sponsors.
This program will analyze the basis of India’s Regulatory environment, the regulations [both current and future] of clinical trials in India, and the challenges faced in the present scenario.
CLICK HERE TO REGISTER FOR THE ARCHIVE
Join Max Neeman's Regulatory experts as they present India's Regulatory
scenario and continuous growth to meet challenges as they arise.
Key Takeaway Points:
– Gain a comprehensive overview of the regulatory requirements in India
– Develop effective processes for obtaining clinical trials authorization
– Clarify the requirements for running clinical trials in special population
– Marketing opportunities in India
|THIS PROGRAM IS INTENDED FOR:|
Industry decision-makers involved in identifying strategic venues for clinical research and looking to understand better the potential of clinical research in India and their Regulatory environment.
||Renu Razdan, PhD, Chief Operating Officer, Max Neeman International
Dr. Renu Razdan heads the business development team in India and looks after business in Europe and the southeast Asian regions. Dr. Renu brings in 10 years of experience. Prior to joining Max Neeman International, she worked for 6 years with Ranbaxy Laboratories Ltd.
Dr. Renu has pursued an ICRETT Fellowship of UICC Geneva, at International Agency for Research on Cancer Lyon (France) and a G.S.F. Fellowship at German Cancer Research Centre (DKFZ), Heidelberg.
||Vandana Pandey, Manager Regulatory Affairs, Max Neeman International
Ms. Vandana Pandey heads the Regulatory Department at Max Neeman International in India. She has seven years of experience in working in Clinical Research and Life Sciences companies.
She has been associated with Max Neeman International for last five years and is responsible for all the Regulatory related activities. Prior to joining Max Neeman International, she worked for two years with CD Pharma India Pvt. Ltd.
Ms. Vandana Pandey holds a Masters Degree in Microbiology from University of Delhi.
||Donald Swankie, MBA, Vice President, USA, Max Neeman International
Mr. Swankie is responsible for the territories of North America and Latin America at Max Neeman. He has twenty years business development and consulting services experience with many in Life Sciences and Clinical Research, in both Biotechnology and U.S. Public Health care forums. Past companies he worked for include Quintiles Transnational and Science Application International [SAIC].
Mr. Swankie holds a Masters Degree from Wake Forest University Babcock Graduate School of Business, 1995. He also holds a BSBA in Business and Economics from St. Peter’s College. He has an Executive education in Life Sciences, Duke University Associated with Max Neeman International for 4 years.
|OUR XTALKS PARTNER FOR THIS EVENT:|
Max Neeman International is a leading India-centric Contract Research Organization and the wholly-owned clinical research subsidiary of Max India Limited, reputed business group with interests in healthcare, clinical research and life insurance. For over a decade, Max Neeman has offered customized services to global pharmaceutical, biotech and device companies in the conduct of clinical and device trials as well as data management. Operational since 2001, Max Neeman is an ISO certified CRO for Site Management, Monitoring, Data Management, Information Security Management Systems and Clinical Investigation of Medical Devices with 6 regional offices, 175 sites across 31 cities, headquarters in New Delhi and USA office based in Cary, North Carolina.
Max Neeman has been awarded 265 trials and 85% of >300 employees are M.D.’s trained in ICH GCP guidelines.
- Project Management
- Regulatory Submission
- Site Monitoring
- Clinical Data Management
- Biometrics and Report Writing
- Site Management
- Device Importation, Warehousing & Distribution
For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email email@example.com